کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2999461 | 1180289 | 2009 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
β-Blocker Use for the Stages of Heart Failure
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
LVSDSOLVDACEMERIT-HFCarvedilol Or Metoprolol European TrialARBHDL-CLVDCAPRICORNHbA1cLVEFNYHAACC/AHA - ACC / AHAMyocardial infarction - آنفارکتوس میوکاردAngiotensin-converting enzyme - آنژیوتانسین تبدیل آنزیمleft ventricular dysfunction - اختلال در بطن چپHOPE - امیدNew York Heart Association - انجمن قلب نیویورکSurvival and Ventricular Enlargement - بقا و انقباض بطن چپBEST - بهترینcoronary artery disease - بیماری عروق کرونرRelative risk - خطر نسبیcomet - دنباله دارSAVE - صرفه جوییCAD - طراحی به کمک رایانه یا کَدconfidence interval - فاصله اطمینانhigh-density lipoprotein cholesterol - لیپوپروتئین پرچگالی یا اچدیالAngiotensin receptor blocker - مسدود کننده گیرنده آنژیوتانسینStudies of Left Ventricular Dysfunction - مطالعات مربوط به اختلالات بطن چپheart failure - نارسایی قلبیHemoglobin A1c - هموگلوبین A1cAmerican College of Cardiology/American Heart Association - کالج آمریکایی قلب و عروق / انجمن قلب آمریکاLV ejection fraction - کسر خروج LVCopernicus - کوپرنیکس
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: β-Blocker Use for the Stages of Heart Failure β-Blocker Use for the Stages of Heart Failure](/preview/png/2999461.png)
چکیده انگلیسی
The 2005 American Heart Association/American College of Cardiology heart failure (HF) guidelines contributed to a renewed focus on “at-risk” patients and emphasized HF as a progressive disease. Patient categorization by stages focused attention on customization of therapy to achieve optimal, evidence-based treatments across the HF continuum. Therapy for risk factors that predispose patients to left ventricular dysfunction or other symptoms may help reduce HF development. β-Blockers are valuable for treatment of HF; however, the class is heterogeneous, and proper β-blocker selection for each HF stage is important. β-Blockers have been used routinely to treat patients with stage A HF with hypertension. Recent controversy regarding the detrimental effects that some β-blockers have on metabolic parameters has raised inappropriate concerns about the use of any β-blocker for diabetes. β-Blockade is standard therapy for the patient with stage B HF who has had a myocardial infarction, but few data are available concerning use in asymptomatic patients with left ventricular dysfunction. Additionally, β-blockers are part of the core therapy for stage C HF and selected patients with stage D HF. This review examines the role and use of β-blockers in each HF stage through an evidence-based approach to provide better understanding of their importance in this progressive disease. PubMed searches (1980-2008) identified large clinical trials that evaluated cardiovascular events and outcomes in any HF stage or hypertension. Search terms were heart failure, hypertension, β-blocker, ACEI, ARB, and calcium channel blocker AND blood pressure coronary artery disease, diabetes, efficacy, left ventricular dysfunction, metabolism, mortality, myocardial infarction, or stroke.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 84, Issue 8, August 2009, Pages 718-729
Journal: Mayo Clinic Proceedings - Volume 84, Issue 8, August 2009, Pages 718-729
نویسندگان
Marc MD,